SCHEMBL3773296

SCHEMBL3773296

CCNC(=O)c1ccc(N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 8/20 0.52
CXCR3 P49682 1/20 0.46
PARP1 P09874 1/20 0.45
TNK2 Q07912 1/20 0.45
TNK1 Q13470 1/20 0.45
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
HPGD P15428 3/20 0.44
HDAC1 Q13547 1/20 0.44
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
TSHR P16473 2/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
KDM4E B2RXH2 2/20 0.42
PKM P14618 1/20 0.42
MAPK1 P28482 1/20 0.42
USP30 Q70CQ3 2/20 0.42
HPGDS O60760 2/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774853 0.93 HRH3 (0.50) HRH3CXCR3ALDH1A1SMN1; SMN2HPGD
SCHEMBL3763097 0.91 CXCR3 (0.49) HRH3CXCR3ALDH1A1SMN1; SMN2HPGD
SCHEMBL3773985 0.91 HRH3 (0.50) HRH3CXCR3ALDH1A1SMN1; SMN2HPGD
SCHEMBL13006725 0.91 HRH3 (0.49) HRH3CXCR3ALDH1A1SMN1; SMN2HPGD
SCHEMBL3766163 0.90 HRH3 (0.53) HRH3CXCR3PARP1TNK1HDAC1
SCHEMBL3770227 0.90 HRH3 (0.48) HRH3CXCR3ALDH1A1SMN1; SMN2HPGD
SCHEMBL3773973 0.90 HRH3 (0.48) HRH3CXCR3ALDH1A1SMN1; SMN2HPGD
SCHEMBL3761209 0.90 HRH3 (0.49) HRH3CXCR3ALDH1A1SMN1; SMN2HPGD
SCHEMBL3767449 0.90 HRH3 (0.49) HRH3CXCR3ALDH1A1SMN1; SMN2HPGD
SCHEMBL3771242 0.89 HRH3 (0.47) HRH3CXCR3ALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 HRH3 2/4885CXCR3 717/4885PARP1 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.